We are a group of privately held biotech companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides, for the treatment of metabolic diseases and rare diseases.
Program: AZP-531, unacylated ghrelin analog, for the treatment of Prader-Willi syndrome
Status: clinical Phase II
Acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) in March 2016
Program: I-HBD1, peptide with bone anabolic properties for the treatment of rare bone diseases and osteoporosis
Status: Lead optimization